share_log

Chardan Capital Reiterates Buy on Silence Therapeutics, Maintains $26 Price Target

Chardan Capital Reiterates Buy on Silence Therapeutics, Maintains $26 Price Target

Chardan Capital重申买入Silence Therapeutics,维持26美元的目标股价
Benzinga ·  2023/08/17 07:47

Chardan Capital analyst Keay Nakae reiterates Silence Therapeutics (NASDAQ:SLN) with a Buy and maintains $26 price target.

Chardan Capital分析师Keay Nakae重申了Silence Therapeutics(纳斯达克股票代码:SLN)的买入,并维持26美元的目标股价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发